Actelion mainly integrates additional innovation into its pipeline through in-licensing, but does not exclude acquisitions should the opportunity arise.
Actelion acquired privately-owned Axovan AG in September 2003, integrating into its pipeline clazosentan, an intravenous endothelin receptor antagonist.
Actelion completed the acquisition of CoTherix Inc. in March 2007, thereby strengthening its PAH franchise by adding Ventavis® to its product offerings in the United States.
Ceptaris Therapeutics Inc.
Actelion completed the acquisition of CeptarisTherapeutics Inc. in September 2013, thereby adding Valchlor™ to its product portfolio.